ClinicalTrials.gg
Not yet recruitingNCT07732413Updated Jul 28, 2026

Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

A Phase 1 interventional study of NLG802 (indoximod Prodrug) and Temozolomide in Progressive Pediatric Brain Cancer, sponsored by Lumos Pharma. Not yet recruiting at 1 site in United States. Open to participants aged 5 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Lumos Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
5 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 1,446 studies in Brain Neoplasms with a site in United States — 234 open to participants now, 354 under way, 18 of them phase 3. Brain Neoplasms · United States.

Planned enrollment
586th of 1,191
30 · median 30
Started
2026
with 54 others
Phase 1
417 of 1,446
52 open now
Primary completion
2030-10
later than 319 of 352 live
Registered
1,432nd of 1,446
by date

Among the 1,446 studies in Brain Neoplasms with a site in United States, this one is the 586th largest by planned enrollment of the 1,191 interventional ones that give a count, is one of 55 that started in 2026, is one of 417 in phase 1, reaches primary completion later than 319 of the 352 other live ones, and was the 1,432nd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

234 of the 1,446 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

229 more — sign in →

All 234 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 5 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,446 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.

Read the detailed description

The study will enroll subjects 5 to 21 years of age with relapsed or refractory primary brain or spinal malignancy of any histology, who have exhausted available curative treatment options. A standard 3+3 dose-escalation design will be used to determine the pediatric maximum tolerated dose (MTD) for NLG802 indoximod prodrug in combination with temozolomide (Treatment Regimen). The MTD of NLG802 for the Treatment Regimen will be the highest dose level where no more than 1 of 6 subjects have (a) Regimen-Limiting Toxicity(/ies) (RLT[s]) in Cycle 1, which will be 28 days duration plus any toxicity-related delay before starting Cycle 2. Toxicity will be defined and graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. All subjects will have timed blood draws for NLG802 pharmacokinetic (PK) analysis in Cycle 1.

03

Conditions studied

  • Progressive Pediatric Brain Cancer

Browse trials for

04

Who can participate

Ages eligible
5 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age must be ≥ 5 years and \< 22 years.
  • Subjects must have or treatment-refractory primary brain or spinal of any histology.
  • Subjects are allowed to have surgical debulking and/or radiation/proton therapy prior to enrollment in this trial.
  • Tumor tissue is required for central review of tissue diagnosis and biomarker correlate studies.
  • Collection of baseline blood samples for required biomarker correlate trials.
  • Performance score: Lansky or performance status score must be ≥ 70.
  • must be ≥ 3 months.
  • ≥ 10 g/dL
  • ≥ 100,000/μL
  • ≥ 1,000/μL
  • ≤ 3-times .
  • Total ≤ 1.5-times upper limit of normal.
  • Adequate renal function
  • Seizure disorders must be well controlled with antiepileptic medication.
  • Subjects must be able to swallow pills.
  • therapy: When necessary for adrenal replacement, subjects may receive hydrocortisone ≤ 1.7 mg/kg/day, maximum dose 70 mg/day (or equivalent).
  • At the time of starting protocol therapy, subjects must be ≥ 21 days from the administration of any prior cytotoxic therapy (including chemotherapy).
  • At the time of starting protocol therapy, subjects must be ≥ 28 days from any radiation or proton therapy.
  • At the time of starting protocol therapy, subjects must be ≥ 28 days from administration of antibody-based immune checkpoint-inhibitor therapies, tumor-directed vaccines, or cellular immune therapies.
  • At the time of starting protocol therapy, subjects must be ≥ 56 days from administration of tumor-directed therapies using infectious agents.
  • At the time of starting protocol therapy, subjects must be ≥ 90 days from a stem cell transplant with growth-factor independent recovery of adequate bone marrow function.
  • Subjects, or their parent for subjects \< 18 years of age, must sign an Form (ICF) indicating that they understand the purpose of the trial and procedures required, including biomarkers, and are willing to participate in the trial.

Exclusion criteria

Exclusion Criteria:

  • Unable to swallow capsules.
  • Active therapy for radiation necrosis.
  • Baseline of > 470 msec at screening, and subjects with known congenital long QT syndrome.
  • cardiovascular disease.
  • Active systemic infection requiring treatment.
  • Active disease that requires systemic therapy.
  • Any known bleeding diathesis.
  • Subjects who are breastfeeding or pregnant women.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NLG802 indoximod prodrug in combination with temozolomide

    Drug: NLG802 (indoximod Prodrug) · Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose in pediatric participants for NLG802 in combination with temozolomide.

    Determined by number of patients with dose limiting toxicities.

    Time frame: Cycle 1, which will be 28 days duration plus any toxicity-related delay before starting Cycle 2.

Secondary outcomes

  1. Incidence of Regimen-limiting toxicities in in pediatric participants for NLG802 in combination with temozolomide.

    Determined by number of patients with regimen limiting toxicities.

    Time frame: Cycle 1, which will be 28 days duration plus any toxicity-related delay before starting Cycle 2.

  2. Pharmacokinetics in pediatric participants for NLG802 in combination with temozolomide

    Serum concentrations (Cmax/Steady State).

    Time frame: Cycle 1, which will be 28 days duration plus any toxicity-related delay before starting Cycle 2.

  3. Overall survival for NLG802 in combination with temozolomide.

    Time frame: Day 1 up to 12 months.

  4. Evidence of efficacy for NLG802 in combination with temozolomide based on change to objective response rate.

    Measured by subjects who achieve complete response, partial response or no response.

    Time frame: Day 1 up to 12 months.

  5. Percentage of patients with adverse events

    Assessment of safety and tolerability of NLG802 in combination with temozolomide.

    Time frame: Day 1 up to 12 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.

Of 204 phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 28, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Oct 8, 2030
CompletionEst.
Oct 8, 2030
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732413
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Oct 8, 2030 (estimated)
Completion
Oct 8, 2030 (estimated)
Last update
Jul 28, 2026

Study contacts

Lumos Pharma
Contact
clinical.trials@lumos-pharma.com
515-296-5555

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE

Start the discussion